Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
93 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
- Iadt Instituto Argentino de Diagnostico Y Tratamiento
CABA, Argentina
- Centro Medico Austral
Capital Federal, Argentina
- Hospital Italiano de la Plata
La Plata, Argentina
- Hospital Privado de la Comunidad
Mar del Plata, Argentina
- Santa Casa de Misericordia de Belo Horizonte
Belo Horizonte, Brazil
- Cto Centro de Tratamento Oncologico Ltda
Belém, Brazil
- Liga Paranaense de Combate Ao Cancer
Curitiba, Brazil
- Fundacao Doutor Amaral Carvalho
Jaú, Brazil
- Hospital Nossa Senhora Da Conceicao S A
Porto Alegre, Brazil
- Nucleo de Oncologia Da Bahia Oncoclinicas
Salvador, Brazil
- Hospital Ana Nery Santa Cruz Do Sul
Santa Cruz do Sul, Brazil
- Fundacao Antonio Prudente A C Camargo Cancer Center
São Paulo, Brazil
- Fundacao Faculdade de Medicina - Instituto Do Cancer Do Estado de Sao Paulo
São Paulo, Brazil
- Servicos de Tratamento Ao Cancer de Taubate Ltda - Instituto Do Cancer Brasil Unidade Taubate
Taubaté, Brazil
- Associacao Feminina de Educacao E Combate Ao Cancer Hospital Santa Rita de Cassia
Vitória, Brazil
- Changzhou No 2 Peoples Hospital
Changzhou, China
- West China Hospital
Chengdoucun, China
- Sichuan Cancer Hospital
Chengdu, China
- the First Affiliated Hospital Sun Yat Sen University
Guangzhou, China
- the First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
- Harbin Medical University Cancer Hospital
Harbin, China
- Huizhou Municipal Central Hospital
Huizhou, China
- Zhongda Hospital Southeast University
Nanjing, China
- Fudan University Shanghai Cancer Center
Shanghai, China
- the First Affiliated Hospital of Xian Jiaotong University
Xi'an, China
- Henan Cancer Hospital
Zhengzhou, China
- Hopital Nord
Marseille, France
- Hopital Pasteur
Nice, France
- Institut Curie
Paris, France
- Universitaetsklinikum Der Rwth Aachen
Aachen, Germany
- Kliniken Essen-Mitte
Essen, Germany
- Universitaetsklinikum Giessen Und Marburg Gmbh
Giessen, Germany
- Thoraxklinik Am Universitatsklinikum Heidelberg
Heidelberg, Germany
- Klinikum Kassel Gmbh
Kassel, Germany
- Universitaetsklinikum Schleswig Holstein Campus Kiel
Kiel, Germany
- Hospital Pulau Pinang
George Town, Malaysia
- University Malaya Medical Centre
Kuala Lumpur, Malaysia
- Hospital Tengku Ampuan Afzan
Kuantan, Malaysia
- Hospital Umum Sarawak
Kuching, Malaysia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Feb 2024
- Primary completion
- 31 May 2027
- Completion
- 30 Jun 2030
- Last update posted
- 6 Jul 2026
- Registered enrollment
- 305
- Registry id
- NCT06120140
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.